ATHE — FY2026 Annual Financial Report Analysis

Overview

Alterity Therapeutics is a Melbourne-based clinical-stage biotech, meaning it has no approved product and no sales; it spends investor money testing a drug candidate in human trials. Its single important asset is ATH434, an oral pill for multiple system atrophy (MSA), a rare and fast-progressing Parkinson's-like brain disease with no approved treatment that slows it down. The company reports in Australian dollars, its financial year ends on June 30, and it files an annual report on Form 20-F with the SEC as a foreign issuer.

In the year to June 30, 2026 (FY2026), the net loss nearly doubled to A$23.4 million from A$12.1 million. About half of that jump is not a change in how much the company is spending on its drug. A$3.7 million of one-off settlement income flattered last year's result, and a A$3.5 million rise in non-cash share-based pay (staff and directors paid in options) lands in this year's. Underneath that, the real change is a move from finishing Phase 2 (mid-sized trials that test whether a drug works) to preparing Phase 3 (the large, final trial regulators usually require before approval). Research spending rose 22%, and in June 2026 the FDA agreed the design of the Phase 3 trial.

At a glance

• A$37.3 million in cash at June 30, up from A$33.2 million, after a A$20.4 million share placement in September 2025. That is enough for "at least the next twelve months" by the company's own statement, but not for the whole Phase 3 trial.
• A$22.5 million operating cash burn, almost double last year's A$11.5 million. The headline overstates the change: no Australian R&D tax refund arrived during FY2026 (A$5.6 million arrived in FY2025), and the A$3.9 million refund for FY2025 landed in July 2026, two weeks after year-end.
• The FDA agreed the Phase 3 design in June 2026. One trial of about 200 patients, treated for 12 months, plus the existing Phase 2 data could be enough for approval. Alterity expects to start Phase 3 trial activities by the end of calendar 2026.

Results table

Figures in Australian dollars. Alterity has no product revenue, so revenue growth and operating margin don't apply.

"n/m" = not meaningful. Percentage changes between two losses aren't a growth rate in the usual sense, so the table describes them as "loss X% larger." The share counts and per-share figures reflect the 50-to-1 share consolidation approved on May 29, 2026: every 50 old shares became one new share, and the Nasdaq-listed American Depositary Share (ADS), a US-traded certificate that stands for a bundle of the Australian shares, was rebased from 600 ordinary shares per ADS to 12. The filing reports loss per ordinary share. The per-ADS figure above is that number multiplied by 12.

Where the money went

• Research and development: A$17.6 million (+22%). The filing attributes the rise to "the initiation of certain research and development studies during the current year." In practice that is Phase 3 preparation. During the year Alterity held two Type C meetings with the FDA, which are formal consultations on specific topics. In March and April 2026 the FDA gave written support for its pharmacology, non-clinical and manufacturing plans. The company also made its first registration batch of ATH434, the drug supply manufactured to approval-grade standards (GMP) for use in the pivotal trial. Payments to suppliers and employees rose A$6.6 million, which the filing says reflects "an acceleration of work towards Phase 3 activities for ATH434."
• General and administrative: A$10.5 million (+92%). The company credits staffing, compliance and consulting costs. The expense note shows the largest single driver: share-based payment expense rose from A$0.98 million to A$4.49 million. Consultant and director costs also rose from A$0.65 million to A$1.48 million, and corporate advisory fees from A$0.36 million to A$1.11 million. Share-based pay is a real cost to shareholders because it dilutes them, but it doesn't use cash.
• Interest income: A$1.7 million (up from A$0.4 million), because the company held more cash after the FY2025 placement of roughly A$40 million.

What the headline numbers hide

• Last year's loss was flattered by one-offs. FY2025 "other income" of A$7.64 million included three non-recurring items: A$1.51 million from the Australian Taxation Office settling a dispute over the FY2020 R&D tax refund, A$1.98 million from settling a dispute with Catalent (a contract drug manufacturer) and A$0.23 million from an insurance settlement. Without them, FY2025's net loss would have been about A$15.9 million, so the like-for-like increase is roughly 47%, not 93%. The recurring R&D tax incentive was similar in both years (A$3.61 million vs A$3.93 million). Under that scheme the Australian government refunds 43.5% of eligible research spending in cash to small companies.
• Non-cash pay accounts for much of the rest. If you also remove share-based payments, the loss goes from about A$14.9 million to about A$18.9 million, a 27% increase. That is close to the 22% rise in R&D and is the cleaner measure of how much faster the core operation is spending.
• The cash burn is distorted by timing, in the other direction. Operating cash outflow almost doubled to A$22.5 million because zero R&D tax refund cash arrived during FY2026, compared with A$5.6 million in FY2025. The A$3.94 million refund for FY2025 arrived in July 2026, just after year-end. It sits in the A$7.7 million of receivables (money owed to the company) at June 30, together with this year's A$3.6 million accrual. On payments alone, gross outflow to suppliers and staff was A$24.1 million, up 38%.
• The rise in cash partly reflects money moved out of term deposits. Year-end cash rose A$4.2 million. That includes a A$7.5 million term deposit that matured during the year (it shows as an investing inflow, and "other current assets" fell from A$8.8 million to A$0.8 million). Counting cash and term deposits together, liquid funds fell from about A$40.7 million to A$37.3 million, even after the A$20.4 million raise.
• Dilution cuts both ways. The loss per share grew only 17% while the total loss grew 93%, because the weighted share count rose 65% after the FY2025 and FY2026 placements. Shareholders own a smaller slice of a company that spends more. Another 66.2 million options are outstanding at exercise prices from A$0.20 to A$1.875. They would bring in A$56.8 million if all were exercised, but that depends entirely on the share price.
• Going concern. The accounts are prepared on a going-concern basis, which means the accounts assume the company keeps operating. The filing does not include "substantial doubt" wording. It ties that conclusion to "the funds raised during the financial year" and states the company "will need to raise substantial additional capital" for its R&D plans.

Takeaway: Alterity's science moved forward this year and its finances did not. The FDA agreed a single 200-patient Phase 3 trial plus the Phase 2 data could support approval, which is about as efficient a path to market as a small biotech can get. But A$37 million of cash (plus about A$7.7 million of tax refunds due) against a roughly A$24 million annual cash spend, before a year-long Phase 3 begins, means another large and probably dilutive capital raise is close to certain before any Phase 3 result.

The science behind the spending

ATH434 is designed to bind excess "loose" iron in the brain, which is thought to drive the clumping of a protein called alpha-synuclein that damages brain cells in MSA. The evidence so far comes from two Phase 2 trials:

• ATH434-201 (77 patients, randomized, double-blind, placebo-controlled). Randomized and double-blind mean patients were randomly assigned to drug or placebo and neither they nor their doctors knew which. At the 50 mg dose, ATH434 slowed decline on the modified UMSARS Part I, a questionnaire on daily-living function (an 11-item version is the FDA-agreed primary endpoint for Phase 3), by about 48% versus placebo at 52 weeks (p=0.02, meaning a result this large would be unlikely by chance alone). The 75 mg dose showed a smaller, non-significant 30% effect. The company attributes this mainly to sicker patients in the 75 mg group: 29% had severe orthostatic hypotension at baseline versus about 4% in the other arms. Orthostatic hypotension is a sharp drop in blood pressure on standing. A reader should note that the higher dose did not work better, and that the explanation rests on a later analysis.
• ATH434-202 (open-label, advanced MSA). Open-label means there was no placebo group and everyone knew they were getting the drug. Disease progression over 12 months was about half the rate seen in historical comparison data (3.5 vs 6.5 points on UMSARS I). Only 7 participants completed the study, so this is supporting evidence at most.
• October 5, 2026 update: at the MDS Congress, Alterity presented a re-analysis that adjusts for baseline disease severity using a spinal-fluid marker of nerve damage (CSF NfL). With that adjustment, the 50 mg dose slowed decline by about 52%. Management says it will build this "learning" into Phase 3 by adjusting for CSF NfL there too (a covariate is a factor the statistics adjust for). Two caveats. The release's footnote says this statistical model was "added post hoc," meaning it was chosen after the data were seen. And it's still a re-analysis of the same 77-patient trial, with no new patients.

Outlook

• Management's plan: finalize the Phase 3 protocol and start Phase 3 trial activities by year-end 2026. The FDA's End-of-Phase 2 minutes, received in July 2026, agreed the study population, the 50 mg twice-daily dose versus placebo, the primary endpoint (11-item UMSARS Part I) and the secondary endpoints, including swallowing and blood-pressure symptom scales. ATH434 already holds Orphan Drug designation in the US and EU, which brings 7 and 10 years of market exclusivity after approval, and FDA Fast Track status, which speeds up the review process.
• Timeline arithmetic: a 200-patient trial with 12 months of treatment per patient, plus time to enroll a rare-disease population, makes a Phase 3 readout before 2028 unlikely. The filing gives no readout date. This estimate is ours.
• Funding: the company says current cash covers "at least the next twelve months." It gives no cost estimate for Phase 3, but a year-long, 200-patient pivotal trial will cost much more than FY2026's spending. Expect a capital raise, a partnership, or exercise of the outstanding options to come before the trial is far along. For ADS holders the key watch item is the size and price of that raise.
• Our view: the regulatory picture is the strongest it has been. A single-trial path with agreed endpoints removes a major uncertainty. The risk has shifted to two questions: whether the 50 mg effect from a 77-patient trial repeats in 200 patients (Phase 2 effects often shrink in Phase 3), and how much dilution it takes to find out. The next 20-F should show R&D spending stepping up sharply if Phase 3 starts on schedule. If it doesn't, the timeline has slipped.